[1]郑珮怡,张馨月,李思雨,等.基于PI3K/Akt/mTOR信号通路探讨中医药防治乳腺癌的研究进展[J].西部中医药,2024,37(02):136-140.[doi:10.12174/j.issn.2096-9600.2024.02.26]
　ZHENG Peiyi,ZHANG Xinyue,LI Siyu,et al.Research Progress on the Intervention of Traditional Chinese Medicine on the Prevention and Treatment of Breast Cancer via PI3K/Akt/mTOR Signaling Pathway[J].Western Journal of Traditional Chinese Medicine,2024,37(02):136-140.[doi:10.12174/j.issn.2096-9600.2024.02.26]
点击复制

基于PI3K/Akt/mTOR信号通路探讨中医药防治乳腺癌的研究进展
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年02期
页码:
136-140
栏目:
研究进展
出版日期:
2024-02-15

文章信息/Info

Title:
Research Progress on the Intervention of Traditional Chinese Medicine on the Prevention and Treatment of Breast Cancer via PI3K/Akt/mTOR Signaling Pathway
作者:
郑珮怡1,2, 张馨月1, 李思雨1, 薛晓红1
1.上海中医药大学附属岳阳中西医结合医院，上海 200437
2.上海市松江区方塔中医医院，上海 201699
Author(s):
ZHENG Peiyi1,2, ZHANG Xinyue1, LI Siyu1, XUE Xiaohong1
1.Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine,Shanghai 200437, China
2.Fangta Hospital of Tradition Chinese Medicine,Songjiang District, Shanghai 201699 China
关键词:
PI3K/Akt/mTOR通路; 乳腺癌; 中医药; 研究进展
Keywords:
PI3K/Akt/mTOR signaling pathway; breast cancer; TCM; research progress
分类号:
R273
DOI:
10.12174/j.issn.2096-9600.2024.02.26
文献标志码:
A
摘要:
磷脂酰肌醇3-蛋白激酶B-哺乳动物雷帕霉素靶蛋白（PI3K/Akt/mTOR）信号传导通路在癌症细胞的增殖、凋亡、分化、侵袭等方面具有重要的调节作用，参与了乳腺癌的发生发展过程，是治疗乳腺癌的重要靶点。文章从PI3K/Akt/mTOR信号通路及靶向药物，PI3K/Akt/mTOR信号通路通过促进血管内皮因子生成、促进细胞增殖、抑制细胞凋亡和促进炎症因子分泌来影响乳腺癌发生发展的机制，中药通过该通路对乳腺癌细胞的增殖、凋亡及耐药的干预作用三个方面进行综述，以期为乳腺癌的治疗药物研发提供参考。
Abstract:
As an important target for the treatment of breast cancer, the phosphatidylinositol-3 kinase (PI3K)/protein kinase B(Akt)/mammalian target of rapamycin (mTOR) signaling pathway can regulate cell proliferation, apoptosis, differentiation and invasion of cancer cells, participating in the occurrence and development of breast cancer. This article reviews the PI3K/Akt/mTOR signaling pathway and targeted drugs, the occurrence and development of breast cancer influnenced by promoting the production of vascular endothelial factor, enhancing cellular proliferation, inhibiting cellular apoptosis and promoting the secretion of inflammatory factors mediated by the signaling pathway, as well as TCM intervention on the proliferation, apoptosis and drug resistance of breast cancer cells via the signaling pathway, and it is designed to provide the reference for the research and development of therapeutic medicine for breast cancer.

相似文献/References:

[1]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101.
　WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(02):101.
[2]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[3]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[4]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[5]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[6]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[7]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[8]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(02):1.
[9]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
　AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(02):7.
[10]朱竹华,许敏菊,张汀荣,等.以家庭为中心的护理模式在完全植入式静脉输液港乳腺癌化疗患者中的应用[J].西部中医药,2016,29(03):114.
　ZHU Zhuhua,XU Minju,ZHANG Dingrong,et al.FCC Applying to Breast Cancer Patients Who Received Chemotherapy by TIVAP[J].Western Journal of Traditional Chinese Medicine,2016,29(02):114.

备注/Memo

备注/Memo:
郑珮怡（1995—），女，硕士学位，医师。研究方向：乳腺疾病的中西医治疗。上海市科学技术委员会2020年度“科技创新行动计划”医学创新研究专项（20Y21901100）；促进市级医院临床技能与临床创新能力三年行动计划项目（SHDC2020CR4057）；上海市中医优势病种培育项目（zybz-2017008）；岳阳医院院级课题青年孵育项目（2019YYQ24）。
更新日期/Last Update: 2024-02-15